Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression

Leukemia

Volumn 27, Issue 5, 2013, Pages 1080-1089

  Tala, I ^a   Chen, R ^a   Hu, T ^a   Fitzpatrick, E R ^a   Williams, D A ^b   Whitehead, I P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

chronic myelogenous leukemia; p210 BCR ABL; Rho GTPase; RhoGEF domain

Indexed keywords

BCR ABL PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL EXPANSION; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; ERYTHROID CELL; GRANULOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84877607982     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.351     Document Type: Article

References (38)

1. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
3. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R et al. Neutrophilicchronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88: 2410-2414.
4. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 1991; 11: 1785-1792.
5. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993; 13: 7587-7595.
6. Maru Y, Afar DE, Witte ON, Shibuya M. The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain. J Biol Chem 1996; 271: 15353-15357.
7. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. BCR-ABLinduced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-185.
8. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 1991; 66: 161-171.
9. Demehri S, O'Hare T, Eide CA, Smith CA, Tyner JW, Druker BJ et al. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia 2009; 24: 226-229.
10. Li S, Ilaria Jr. RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399-1412.
11. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
12. Whitehead IP, Campbell S, Rossman KL, Der CJ. Dbl family proteins. Biochim Biophys Acta 1997; 1332: F1-23.
13. Daubon T, Chasseriau J, Ali AE, Rivet J, Kitzis A, Constantin B et al. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs. Oncogene 2008; 27: 2673-2685.
14. Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 2008; 27: 2064-2071.
15. Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Oncogene 2003; 22: 6445-6454.
16. Kelliher M, Knott A, McLaughlin J, Witte ON, Rosenberg N. Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ ABL oncogene. Mol Cell Biol 1991; 11: 4710-4716.
17. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
18. Olabisi OO, Mahon GM, Kostenko EV, Liu Z, Ozer HL, Whitehead IP. Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res 2006; 66: 6250-6257.
19. Korus M, Mahon GM, Cheng L, Whitehead IP. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 2002; 21: 4601-4612.
20. Thomas EK, Cancelas JA, Chae HD, Cox AD, Keller PJ, Perrotti D et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007; 12: 467-478.
21. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996; 2: 876-882.
22. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829-3840.
23. Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control 2009; 16: 100-107.
24. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479-492.
25. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E et al. The protooncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996; 12: 839-846.
26. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000; 96: 2269-2276.
27. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000; 95: 2118-2125.
28. Gallagher ED, Gutowski S, Sternweis PC, Cobb MH. RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity. J Biol Chem 2004; 279: 1872-1877.
29. Kobayashi K, Takahashi M, Matsushita N, Miyazaki J, Koike M, Yaginuma H et al. Survival of developing motor neurons mediated by Rho GTPase signaling pathway through Rho-kinase. J Neurosci 2004; 24: 3480-3488.
30. Yoshida T, Clark MF, Stern PH. The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival. J Cell Biochem 2009; 106: 896-902.
31. Zhu S, Korzh V, Gong Z, Low BC. RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek/Erk pathway. Oncogene 2008; 27: 1580-1589.
32. Zhang S, Zhou X, Lang RA, Guo F. RhoA of the Rho family small GTPases is essential for B lymphocyte development. PloS one 7: e33773.
33. Burthem J, Rees-Unwin K, Mottram R, Adams J, Lucas GS, Spooncer E et al. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. Leukemia 2007; 21: 1708-1714.
34. Pompetti F, Spadano A, Sau A, Mennucci A, Russo R, Catinella V et al. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate. Leuk Res 2007; 31: 563-567.
35. Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007; 127: 642-650.
36. Morgan GJ, Wiedemann LM, Chan LC, Price CM, Kanfer EJ, Galton DA. A case of M-BCR-rearranged, Philadelphia-positive AML that relapsed as chronic phase CML. Blood 1990; 75: 317-318.
37. Price CM, Rassool F, Shivji MK, Gow J, Tew CJ, Haworth C et al. Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia. Blood 1988; 72: 1829-1832.
38. Sharma P, Dhingra KK, Roy S, Singh T. An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia. J Pediatr Hematol Oncol 2009; 31: 220-221.